+

Laboratory Turnaround Time for FLT3 testing in relapsed acute myeloid leukemia needs improvement



Laboratory Turnaround Time for FLT3 testing in relapsed acute myeloid leukemia needs improvement

Researchers at Diaceutics uncovered the need for faster laboratory testing turnaround times (TAT) in an abstract accepted for publication by the European Hematology Association (EHA) for its annual meeting in June 2019. The abstract, entitled “FLT3 Testing in Relapsed Acute Myeloid Leukemia Setting Is Becoming Increasingly Common, But Laboratory Turnaround Times (TAT) May Be a Barrier to Treatment With Second Generation FLT3 Inhibitors,” analyzed the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. 

The researchers discovered an increase in awareness of the need for retesting in FLT3 and the need for faster TAT in the relapsed setting. However, the TAT results did not demonstrate an improvement in actual TAT, with the average TAT remaining suboptimal at 12.6 days., This may be due to the lack of an approved FLT3 inhibitor for secondline treatment in Europe. Lab TAT will be a key metric to monitor over the coming 12 to 18 months. 

For more information on these findings, contact services@diaceutics.com. 

Read Full Abstract here. 

Webinars & Podcasts

Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases....
Liquid Biopsy in NSCLC
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports

Publications

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications